This is the question with the most history attached to it, so it is worth being precise about what changed and when.
In 2002 the Women’s Health Initiative reported early results that were communicated, both by the investigators and by the press, as showing that hormone therapy increased breast cancer and cardiovascular risk. Prescribing collapsed worldwide within eighteen months. A generation of women went through menopause without treatment that would have helped them, and a generation of doctors trained without learning to prescribe it.
Subsequent reanalysis showed the original communication had flattened out crucial distinctions: the average participant was sixty-three, well over a decade past her final period, and the findings in women in their fifties looked substantially different. In November 2025 the FDA removed the broad boxed warnings from menopausal hormone therapy labelling, including from low-dose vaginal preparations where the systemic absorption is negligible.
What that does and does not mean for you
It means the default framing has changed. The conversation now starts from “is this appropriate for you” rather than from a black-box warning that ended it before it began.
It does not mean the answer is yes for everyone. A personal history of breast cancer, of blood clots, or of liver disease all change the calculation, sometimes decisively. What it means is that those are the questions, and that a blanket refusal to discuss it is no longer defensible.
What this page cannot do
It cannot tell you whether to take it. Nothing that does not know your history, your blood pressure, your family history and what your symptoms are actually costing you can do that honestly, and any website that offers to is selling you something.